Skip to content

Nasdaq · CIK 0001607678

VKTX Viking Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing Jun 3, 2026. Close $28.51 on Oct 9, 2026, +8% from the 52-week low and -32% from the high.

Viking Therapeutics, Inc. (VKTX) has 26 SEC Form 4 filings on file from 10 insiders, the latest filed on Jun 3, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

18 open-market trades have been scored at VKTX. The newest: Neil William Aubuchon (Chief Commercial Officer) bought $150k of stock on Mar 10, 2026, filed Mar 10, 2026, scored 38 (weak). The largest of the 18 shown: Greg Zante (Chief Financial Officer) sold $10M on Oct 28, 2024, scored 37 (weak), under a 10b5-1 plan. 4 insiders sold within 14 days of each other around Jan 2, 2026.

VKTX closed at $28.51 on Oct 9, 2026, 8% above its 52-week low and 32% below its 52-week high.

7 Form 144 notices of planned sales are on file, the latest filed Jan 6, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company

Price and insider trades, last year

VKTXOct 9, 2026 · close 28.51

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Viking Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
38WeakNeil William Aubuchon
Chief Commercial Officer
buy
$150k
4,475 shares
-+73% from low-18% from high
39WeakMatthew W Foehr
director
sell
$562k
16,000 shares
-11%+77% from low-17% from high
65NotableBrian Lian
President & CEO
sell
$7.7M
233,409 shares
-9%+61% from low-24% from high
65NotableMarianna Mancini
Chief Operating Officer
sell
$1.9M
57,661 shares
-12%+61% from low-24% from high
67NotableGreg Zante
Chief Financial Officer
sell
$1.9M
57,661 shares
-23%+61% from low-24% from high
65NotableBrian Lian
President & CEO
sell
$1.4M
38,989 shares
-2%+75% from low-53% from high
47ModerateMarianna Mancini
Chief Operating Officer
sell
$216k
6,185 shares
-2%+75% from low-53% from high
60NotableCharles A Rowland Jr
director
sell
$2.1M
60,000 shares
-67%+80% from low-52% from high
49ModerateGreg Zante
Chief Financial Officer
sell
$216k
6,185 shares
-3%+75% from low-53% from high
61NotableBrian Lian
President & CEO
sell
$748k
26,889 shares
-1%+41% from low-64% from high
45ModerateMarianna Mancini
Chief Operating Officer
sell
$118k
4,266 shares
-1%+41% from low-64% from high
47ModerateGreg Zante
Chief Financial Officer
sell
$118k
4,266 shares
-2%+41% from low-64% from high
46ModerateSarah Kathryn Rouan
director
buy
$30k
1,240 shares
-0% from low-69% from high
46ModerateSarah Kathryn Rouan
director
buy
$30k
1,240 shares
-0% from low-69% from high
26WeakLawson Macartney
director
sell
$137k
2,000 shares
-4%-
37WeakGreg Zante
Chief Financial Officer
sell
$10M
131,687 shares
-47%-
38WeakSarah Kathryn Rouan
director
sell
$890k
11,000 shares
-100%-
40ModerateJ Matthew Singleton
director
sell
$1.3M
16,000 shares
-63%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Jan 6, 2025 BRIAN LIAN
Officer
194,490
0.17% of outstanding
$8.3MJan 6, 2025none
Jan 6, 2025 MARIANNA MANCINI
Officer
54,215
0.05% of outstanding
$2.3MJan 6, 2025none
Jan 6, 2025 GREG ZANTE
Officer
50,309
0.05% of outstanding
$2.2MJan 6, 2025none
Nov 8, 2024 LAWSON MACARTNEY
Director
2,000
0.00% of outstanding
$137kNov 8, 2024none
Oct 28, 2024 GREG ZANTE
Officer
131,687
0.12% of outstanding
$10MOct 28, 2024$922k
Oct 25, 2024 Rouan Sarah Kathryn
Director
11,000
0.01% of outstanding
$889kOct 25, 2024none
Oct 25, 2024 SINGLETON J MATTHEW
Director
16,000
0.01% of outstanding
$1.3MOct 25, 2024$3.3M

Transactions

The newest 50 of 86 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jun 1, 2026Hubert C Chen
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+190,000$0.00$0190,000Jun 3, 2026
Mar 10, 2026Neil William Aubuchon
Chief Commercial Officer
POpen-market purchase
Common Stock, par value $0.00001 per share
+4,475$33.50$150k4,475Mar 10, 2026
Jan 12, 2026Neil William Aubuchon
Chief Commercial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+180,000$0.00$0180,000Jan 26, 2026
Jan 2, 2026Marianna Mancini
Chief Operating Officer
AGrant or award
Common Stock, par value $0.00001 per share
+41,000$0.00$0434,802Jan 5, 2026
Jan 2, 2026Greg Zante
Chief Financial Officer
AGrant or award
Common Stock, par value $0.00001 per share
+41,000$0.00$0215,483Jan 5, 2026
Jan 2, 2026Brian Lian
President & CEO
AGrant or award
Common Stock, par value $0.00001 per share
+78,400$0.00$02,508,620Jan 5, 2026
Jan 2, 2026Charles A Rowland Jr
director
AGrant or award
Common Stock, par value $0.00001 per share
+3,150$0.00$033,150Jan 5, 2026
Jan 2, 2026J Matthew Singleton
director
AGrant or award
Common Stock, par value $0.00001 per share
+3,150$0.00$012,650Jan 5, 2026
Jan 2, 2026Matthew W Foehr
director
MOption exercise
Common Stock, par value $0.00001 per share
+16,000$3.33$53k148,036Jan 5, 2026
Jan 2, 2026Sarah Kathryn Rouan
director
AGrant or award
Common Stock, par value $0.00001 per share
+3,150$0.00$04,390Jan 5, 2026
Jan 2, 2026Lawson Macartney
director
AGrant or award
Common Stock, par value $0.00001 per share
+3,150$0.00$051,115Jan 5, 2026
Jan 2, 2026Charles A Rowland Jr
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,400$0.00$020,400Jan 5, 2026
Jan 2, 2026J Matthew Singleton
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,400$0.00$020,400Jan 5, 2026
Jan 2, 2026Greg Zante
Chief Financial Officer
AGrant or award
Common Stock, par value $0.00001 per share
+32,049$0.00$0247,532Jan 5, 2026
Jan 2, 2026Brian Lian
President & CEO
AGrant or award
Common Stock, par value $0.00001 per share
+224,080$0.00$02,732,700Jan 5, 2026
Jan 2, 2026Lawson Macartney
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,400$0.00$020,400Jan 5, 2026
Jan 2, 2026Marianna Mancini
Chief Operating Officer
AGrant or award
Common Stock, par value $0.00001 per share
+32,049$0.00$0466,851Jan 5, 2026
Jan 2, 2026Matthew W Foehr
director
SOpen-market sale
Common Stock, par value $0.00001 per share
-16,000$35.11$562k132,036Jan 5, 2026
Jan 2, 2026Sarah Kathryn Rouan
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,400$0.00$020,400Jan 5, 2026
Jan 5, 2026Marianna Mancini
Chief Operating Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-31,961$32.29$1.0M434,890Jan 5, 2026
Jan 2, 2026Matthew W Foehr
director
AGrant or award
Common Stock, par value $0.00001 per share
+3,150$0.00$0135,186Jan 5, 2026
Jan 5, 2026Brian Lian
President & CEO
SOpen-market sale
Common Stock, par value $0.00001 per share
-132,454$32.29$4.3M2,600,246Jan 5, 2026
Jan 5, 2026Greg Zante
Chief Financial Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-31,961$32.30$1.0M215,571Jan 5, 2026
Jan 5, 2026Marianna Mancini
Chief Operating Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-13,600$33.37$454k421,290Jan 5, 2026
Jan 2, 2026Matthew W Foehr
director
MOption exercise
Stock Option (Right to Buy)derivative
-16,000$0.00$00Jan 5, 2026
Jan 5, 2026Brian Lian
President & CEO
SOpen-market sale
Common Stock, par value $0.00001 per share
-53,279$33.38$1.8M2,546,967Jan 5, 2026
Jan 5, 2026Greg Zante
Chief Financial Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-13,900$33.38$464k201,671Jan 5, 2026
Jan 2, 2026Matthew W Foehr
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,400$0.00$020,400Jan 5, 2026
Jan 5, 2026Marianna Mancini
Chief Operating Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-10,500$34.22$359k410,790Jan 5, 2026
Jan 5, 2026Brian Lian
President & CEO
SOpen-market sale
Common Stock, par value $0.00001 per share
-41,276$34.22$1.4M2,505,691Jan 5, 2026
Jan 5, 2026Greg Zante
Chief Financial Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-10,300$34.24$353k191,371Jan 5, 2026
Jan 5, 2026Marianna Mancini
Chief Operating Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-1,600$35.07$56k409,190Jan 5, 2026
Jan 5, 2026Brian Lian
President & CEO
SOpen-market sale
Common Stock, par value $0.00001 per share
-6,400$35.07$224k2,499,291Jan 5, 2026
Jan 5, 2026Greg Zante
Chief Financial Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-1,500$32.09$48k189,891Jan 5, 2026
Jan 2, 2026Greg Zante
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+91,000$0.00$091,000Jan 5, 2026
Jan 2, 2026Brian Lian
President & CEO
AGrant or award
Stock Option (Right to Buy)derivative
+176,300$0.00$0176,300Jan 5, 2026
Jan 2, 2026Marianna Mancini
Chief Operating Officer
AGrant or award
Stock Option (Right to Buy)derivative
+91,000$0.00$091,000Jan 5, 2026
Oct 27, 2025Brian Lian
President & CEO
AGrant or award
Common Stock, par value $0.00001 per share
+70,084$0.00$02,458,098Oct 28, 2025
Oct 27, 2025Marianna Mancini
Chief Operating Officer
AGrant or award
Common Stock, par value $0.00001 per share
+11,117$0.00$0388,652Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
AGrant or award
Common Stock, par value $0.00001 per share
+16,000$4.48$72k46,000Oct 28, 2025
Oct 27, 2025Greg Zante
Chief Financial Officer
AGrant or award
Common Stock, par value $0.00001 per share
+11,117$0.00$0179,777Oct 28, 2025
Oct 28, 2025Brian Lian
President & CEO
SOpen-market sale
Common Stock, par value $0.00001 per share
-38,989$35.01$1.4M2,419,109Oct 28, 2025
Oct 28, 2025Marianna Mancini
Chief Operating Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-6,185$35.00$216k382,467Oct 28, 2025
Oct 28, 2025Greg Zante
Chief Financial Officer
SOpen-market sale
Common Stock, par value $0.00001 per share
-6,185$35.00$216k173,592Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
AGrant or award
Common Stock, par value $0.00001 per share
+22,000$5.80$128k68,000Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
AGrant or award
Common Stock, par value $0.00001 per share
+22,000$4.88$107k90,000Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
SOpen-market sale
Common Stock, par value $0.00001 per share
-60,000$35.57$2.1M30,000Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
MOption exercise
Stock Option (Right to Buy)derivative
-16,000$0.00$00Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
MOption exercise
Stock Option (Right to Buy)derivative
-22,000$0.00$00Oct 28, 2025
Oct 27, 2025Charles A Rowland Jr
director
MOption exercise
Stock Option (Right to Buy)derivative
-22,000$0.00$00Oct 28, 2025
50 of 86 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about VKTX

Answered from the filings on this page, as of the latest one.

Are insiders buying VKTX?

No. In the last 90 days no insider at Viking Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade VKTX on the open market?

Neil William Aubuchon (Chief Commercial Officer) bought $150k of VKTX on Mar 10, 2026 and filed the Form 4 on Mar 10, 2026. InsiderTell scored 38 (weak).

How many insiders file Form 4 at Viking Therapeutics, Inc.?

10 people have filed a Form 4 at Viking Therapeutics, Inc., among them Neil William Aubuchon (Chief Commercial Officer), Hubert C Chen (Chief Medical Officer), Matthew W Foehr (CEO, president and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

VKTX insider trading: Viking Therapeutics, Inc. | InsiderTell